QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
NCT ID: NCT00581997
Last Updated: 2020-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
8 participants
INTERVENTIONAL
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
QAX576
QAX576
2
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QAX576
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both men and women must be willing to use two forms of contraception. Additional information regarding this requirement is available at screening
Exclusion Criteria
* Should not have participated in another clinical study within 4 weeks of study start
* Smokers are not eligible for participation
* Blood loss of donation of 400 mL or more within 2 months of study start
* Pregnant women or women who are breast feeding
* Past medical history of clinically significant ECG abnormalities
* Connective tissue disorders other than systemic sclerosis.
* Active infection or history of systemic parasitic infection
* History of immunodeficiency diseases, including a positive HIV test result
* History of drug or alcohol abuse within 12 months of study start
* Any condition that may compromise patient safety
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: PRINCIPAL_INVESTIGATOR
Novartis Pharmaceuticals
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CQAX576A2201 from the Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CQAX576A2201
Identifier Type: -
Identifier Source: org_study_id